Effect of asenapine and iloperidone on weight gain in patients of psychosis: a prospective study
Keywords:Asenapine, Iloperidone, Psychosis, Weight gain
Background: Second generation or atypical antipsychotics are the most commonly used effective drugs for psychotic disorders like schizophrenia. But the drawback with the use of these drugs is that they tend to cause adverse effects; among which weight gain is an important one with risk of diabetes and adverse cardiovascular events. Weight gain is less with newer atypical antipsychotics. This study was conducted to compare weight gain with two newer atypical antipsychotic drugs, Asenapine and Iloperidone
Methods: It is a prospective study conducted on a total of 60 subjects who were diagnosed with schizophrenia or acute psychosis according to ICD 10 guidelines. The subjects were divided into two groups of 30 each. They received Asenapine (5-20 mg) and Iloperidone (8-24 mg) and were followed-up with weight measurements at baseline, week 1, week 3 and week 6.
Results: Out of 60 subjects, 5 patients were lost to follow-up. The mean weight gain in each of the groups was 2.18±1.84 kg with Iloperidone and 1.63±1.28kg with Asenapine, which was statistically not significant. Weight gain was dose-dependent, 3.63kg mean weight gain with 15-20 mg Asenapine and 3.45 kg with 18-24 mg Iloperidone; which was statistically significant.
Conclusions: Weight gain was seen with both the atypical antipsychotic drugs, Asenapine and Iloperidone; which was only of mild to moderate degree. Among the two study drugs, Iloperidone showed more weight gain than Asenapine.
Howes OD, Bhatnagar A, Gaughran FP, Amiel SA, Murray RM, Pilowsky LS. A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance. Am J Psychiat. 2004;161(2):361-3.
Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta‐analysis. World Psychiatr. 2015;14(3):339-47.
Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta-analysis. Schizophr Bull. 2013;39(2):306-18.
Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large‐scale meta‐analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatr. 2017;16(2):163-80.
Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch General Psychiatr. 2007;64(10):1123-31.
Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 2004;66(1):51-7.
De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS drugs. 2012;26:733-59.
Saphris (asenapine) sublingual tablets (package insert). Available at: http://www.spfiles.com/pisaphrisv1.pdf. Accessed on 20 November 2022.
Fanapt (iloperidone) tablets (package insert). Available at: http://www.pharma.us.novrtis.com/product/pi/ pdf/fanapt.pdf. Accessed on 20 November 2022.
Jin H, Mosweu I. The societal cost of schizophrenia: a systematic review. Pharmacoeconomics. 2017;35:25-42.
Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163-96.
Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatr. 2020;7(1):64-77.
Citrome L. New antipsychotic medications: what advantages do they offer?. Postgrad Med. 1997;101(2):207-14.
Vishal S, Beg MA, Dutta SB, Khatri S, Garg S, Singh NK, et al. Comparative evaluation of cost-effectiveness between typical antipsychotic haloperidol and atypical antipsychotics olanzapine, risperidone and aripiprazole in the treatment of stable schizophrenia. Int J Basic Clin Pharmacol. 2017;6(8):1965.